A randomized, double-blind, controled phase 3 study of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in subjects with previously untreated advanced or metastatic renal cell carcinoma of intermediate to poor risk
- Gurney, Howard (Primary Chief Investigator)
- Butala, Radhika, (Clinical Trial Unit Staff)
- Chapman, Nicola, (Clinical Trial Unit Staff)
- Parshionikar, Abhijit, (Clinical Trial Unit Staff)
- Rajasekharan Nair, Archana, (Clinical Trial Unit Staff)
Project: Other